Overcoming immune resistance in hepatocellular carcinoma: insights into mechanisms, predictive factors, and interventional strategies
Frontiers in Immunology · 2026
DOI: 10.3389/fimmu.2026.1804366 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Immunology, 2026. Verfasst von Zhenxao Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, The Second Hospital of Jilin University, Changchun, Jilin, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Drug Resistance, Neoplasm, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 159 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Recently, immune checkpoint inhibitors, both as monotherapy and in combination regimens, have become a mainstay of systemic therapies for patients with advanced or unresectable hepatocellular carcinoma (HCC). However, evidence from clinical trials and real-world studies consistently demonstrates that only a subset of patients achieves long-term clinical benefit. A significant proportion of patients exhibit primary resistance or develop acquired resistance during treatment, resulting in low objective response (OR) rates, brief illness control duration, and increased complexity of successive therapeutic lines. The primary constraint in modern practice stems from the lack of reliable, generalizable, and therapeutically applicable techniques for predicting resistance to immunotherapy. This deficiency severely limits effective pretreatment risk stratification, early detection of resistance, and the formulation of rational strategies to overcome immune resistance. Therefore, this review systematically summarizes the primary causes of resistance to HCC immunotherapy, evaluates recent developments in resistance prediction, and focuses particular attention on emerging intervention strategies and potential clinical translation. Thus, it aims to offer practical guidance for enhancing treatment decision-making and to inform the development of future prospective validation studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Surgery, The Second Hospital of Jilin University, Changchun, Jilin, China.
- Department of Laboratory Medicine, The Second Hospital of Jilin University, Changchun, Jilin, China.
Zitieren
APA
Wang, Z., Wu, J., Li, Q., & Wen, X. (2026). Overcoming immune resistance in hepatocellular carcinoma: insights into mechanisms, predictive factors, and interventional strategies. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1804366
Vancouver
Wang Z, Wu J, Li Q, Wen X. Overcoming immune resistance in hepatocellular carcinoma: insights into mechanisms, predictive factors, and interventional strategies. Frontiers in Immunology. 2026. doi:10.3389/fimmu.2026.1804366
BibTeX
@article{Wang2026,
author = {Wang, Zhenxao and Wu, Jun and Li, Qiao and Wen, Xin},
title = {Overcoming immune resistance in hepatocellular carcinoma: insights into mechanisms, predictive factors, and interventional strategies},
journal = {Frontiers in Immunology},
year = {2026},
doi = {10.3389/fimmu.2026.1804366}
}
EUVIMED